<p>Osaic Holdings Inc. 在最近向证券交易委员会（SEC）提交的 13F 表格中表示，在第二季度将其在 TG Therapeutics, Inc.（NASDAQ:TGTX - 免费报告）的持股减少了 25.8%。该基金在此期间出售了 39,445 股后，持有该生物制药公司 113,345 股股票。Osaic Holdings Inc. 在最近的报告期末持有 TG Therapeutics 约 0.07% 的股份，价值 4,079,000 美元。</p>
<p>获取 <strong>TG Therapeutics</strong> 警报：</p>
<ul>
<li>六月最被做空的股票：持有、做空还是挤压？</li>
</ul>
<p>其他大型投资者也增加或减少了对该公司的投资。Ameritas Advisory Services LLC 在第二季度购买了 TG Therapeutics 的新头寸，价值约 25,000 美元。Johnson Financial Group Inc. 在第二季度购买了 TG Therapeutics 的新头寸，价值 25,000 美元。SVB Wealth LLC 在第一季度购买了 TG Therapeutics 的新股份，价值约 37,000 美元。Private Wealth Asset Management LLC 在第二季度购买了 TG Therapeutics 的新股份，价值约 37,000 美元。最后，EverSource Wealth Advisors LLC 在第二季度将其在 TG Therapeutics 的持股增加了 86.3%。EverSource Wealth Advisors LLC 目前持有该生物制药公司 1,237 股股票，价值 45,000 美元，此前在上个季度又购买了 573 股。机构投资者持有该公司 58.58% 的股票。</p>
<h2>TG Therapeutics 价格表现</h2>
<p>NASDAQ TGTX 周四开盘价为 31.07 美元。该公司的债务与股本比率为 0.40，速动比率为 2.89，流动比率为 3.82。该公司的市值为 49.3 亿美元，市盈率为 11.18，贝塔值为 2.01。该公司的 50 日移动平均价格为 32.23 美元，200 日移动平均价格为 33.34 美元。TG Therapeutics, Inc. 的 52 周低点为 25.28 美元，52 周高点为 46.48 美元。</p>
<ul>
<li>TG Therapeutics 股票 300% 的反弹仍有潜力</li>
</ul>
<p>TG Therapeutics（NASDAQ:TGTX - 获取免费报告）最近在 11 月 3 日星期一公布了其财报。该生物制药公司报告季度每股收益为 2.43 美元，超出分析师一致预期的 0.24 美元，差额为 2.19 美元。TG Therapeutics 的净利润率为 84.13%，股本回报率为 133.24%。该公司在本季度的收入为 1.6171 亿美元，而一致预期为 1.5212 亿美元。在去年同期，该公司每股收益为 0.02 美元。该公司的收入同比增长 92.7%。卖方分析师预测 TG Therapeutics, Inc. 本财年将发布 0.08 美元的每股收益。</p>
<h2>内部人士下注</h2>
<p>在其他 TG Therapeutics 的新闻中，董事 Yann Echelard 于 11 月 24 日星期一出售了 5,000 股该公司的股票，交易价格为 32.57 美元，总交易额为 162,850.00 美元。出售后，该董事持有 223,816 股公司的股票，价值约 7,289,687.12 美元。此次交易使其持股减少了 2.19%。该交易已在向证券交易委员会提交的文件中披露，文件可在此链接查看。公司内部人士持有该公司 10.64% 的股票。</p>
<h2>分析师设定新目标价</h2>
<p>几家券商对 TGTX 发表了评论。HC Wainwright 于 10 月 6 日星期一在一份研究报告中开始覆盖 TG Therapeutics。他们对该股票给予了 “买入” 评级，目标价为 60.00 美元。华尔街 Zen 在 12 月 14 日星期日的研究报告中将 TG Therapeutics 的评级从 “持有” 上调至 “买入”。Weiss Ratings 在周一的研究报告中重申了对 TG Therapeutics 的 “持有（c+）” 评级。B. Riley 在 11 月 4 日星期二的研究报告中将 TG Therapeutics 的评级上调至 “强力买入”。最后，摩根大通在 11 月 3 日星期一的研究报告中将 TG Therapeutics 的目标价从 46.00 美元上调至 49.00 美元，并给予该公司 “增持” 评级。一位研究分析师对该股票给予了强力买入评级，两位给予了买入评级，两位给予了持有评级。根据 MarketBeat，TG Therapeutics 目前的共识评级为 “适度买入”，平均目标价为 50.25 美元。</p>
<p><strong>查看我们关于 TGTX 的最新研究报告</strong></p>
<h2>TG Therapeutics 公司简介</h2>
<p>（免费报告）</p>
<p>TG Therapeutics, Inc. 是一家总部位于纽约市的临床阶段生物制药公司，专注于开发针对血液恶性肿瘤和自身免疫性疾病的靶向疗法。该公司的研究策略侧重于通过新型抗体和小分子药物调节 B 细胞生物学。自 2003 年成立以来，TG Therapeutics 已建立了一个多元化的产品组合，旨在满足肿瘤学和免疫学领域未满足的医疗需求。</p>
<p>在 2022 年 12 月，TG Therapeutics 实现了其第一个商业里程碑，当 ublituximab-xiiy（与 Biogen 合作市场化的 Briumvi®）获得美国批准。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 TG Therapeutics</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “3 美元 AI 奇迹股票” 即将爆发</li>
<li>是否可以从资本利得税中扣除任何费用？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>忘记 AI，这将是下一个重大科技突破</li>
</ul>
<p><strong>想看看其他对 TGTX 持有股份的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 TG Therapeutics, Inc.（NASDAQ:TGTX - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEdUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEdUWA"/></p>
<p><em>此即时新闻警报由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 $1,000 在 TG Therapeutics 吗？</h2>
<p>在考虑 TG Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 TG Therapeutics 并不在名单上。</p>
<p>虽然 TG Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TG治疗

<p>Osaic Holdings Inc. 在第二季度减少了对 TG Therapeutics 的持股比例，下降了 25.8%，出售了 39,445 股。TG Therapeutics 的股票开盘价为 31.07 美元，市值为 49.3 亿美元。分析师预测该股票的评级为适度买入，目标价为 50.25 美元。该公司报告了强劲的收益，净利润率为 84.13%，营收同比增长 92.7%</p>

<p>Osaic Holdings Inc. cut its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 25.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 113,345 shares of the biopharmaceutical company's stock after selling 39,445 shares during the period. Osaic Holdings Inc. owned approximately 0.07% of TG Therapeutics worth $4,079,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Osaic Holdings Inc. 在最近向证券交易委员会（SEC）提交的 13F 表格中表示，在第二季度将其在 TG Therapeutics, Inc.（NASDAQ:TGTX - 免费报告）的持股减少了 25.8%。该基金在此期间出售了 39,445 股后，持有该生物制药公司 113,345 股股票。Osaic Holdings Inc. 在最近的报告期末持有 TG Therapeutics 约 0.07% 的股份，价值 4,079,000 美元。</p>
</div><p>Get <strong>TG Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>TG Therapeutics</strong> 警报：</p>
</div><ul>
<li>The Most Shorted Stocks in June: Hold, Short, or Squeeze?</li>
</ul>
<div class="lb-trans"><ul>
<li>六月最被做空的股票：持有、做空还是挤压？</li>
</ul>
</div><p>Other large investors have also added to or reduced their stakes in the company. Ameritas Advisory Services LLC bought a new position in TG Therapeutics in the second quarter worth approximately $25,000. Johnson Financial Group Inc. purchased a new position in TG Therapeutics during the second quarter valued at $25,000. SVB Wealth LLC purchased a new stake in shares of TG Therapeutics during the 1st quarter valued at about $37,000. Private Wealth Asset Management LLC bought a new stake in shares of TG Therapeutics in the 2nd quarter valued at approximately $37,000. Finally, EverSource Wealth Advisors LLC lifted its position in TG Therapeutics by 86.3% in the second quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 573 shares during the last quarter. Institutional investors own 58.58% of the company's stock.</p>
<div class="lb-trans"><p>其他大型投资者也增加或减少了对该公司的投资。Ameritas Advisory Services LLC 在第二季度购买了 TG Therapeutics 的新头寸，价值约 25,000 美元。Johnson Financial Group Inc. 在第二季度购买了 TG Therapeutics 的新头寸，价值 25,000 美元。SVB Wealth LLC 在第一季度购买了 TG Therapeutics 的新股份，价值约 37,000 美元。Private Wealth Asset Management LLC 在第二季度购买了 TG Therapeutics 的新股份，价值约 37,000 美元。最后，EverSource Wealth Advisors LLC 在第二季度将其在 TG Therapeutics 的持股增加了 86.3%。EverSource Wealth Advisors LLC 目前持有该生物制药公司 1,237 股股票，价值 45,000 美元，此前在上个季度又购买了 573 股。机构投资者持有该公司 58.58% 的股票。</p>
</div><h2>TG Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>TG Therapeutics 价格表现</h2>
</div><p>NASDAQ TGTX opened at $31.07 on Thursday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.89 and a current ratio of 3.82. The company has a market cap of $4.93 billion, a PE ratio of 11.18 and a beta of 2.01. The firm's 50 day moving average price is $32.23 and its 200-day moving average price is $33.34. TG Therapeutics, Inc. has a 52-week low of $25.28 and a 52-week high of $46.48.</p>
<div class="lb-trans"><p>NASDAQ TGTX 周四开盘价为 31.07 美元。该公司的债务与股本比率为 0.40，速动比率为 2.89，流动比率为 3.82。该公司的市值为 49.3 亿美元，市盈率为 11.18，贝塔值为 2.01。该公司的 50 日移动平均价格为 32.23 美元，200 日移动平均价格为 33.34 美元。TG Therapeutics, Inc. 的 52 周低点为 25.28 美元，52 周高点为 46.48 美元。</p>
</div><ul>
<li>TG Therapeutics Stock 300% Rally Has Legs Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>TG Therapeutics 股票 300% 的反弹仍有潜力</li>
</ul>
</div><p>TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 EPS for the quarter, topping analysts' consensus estimates of $0.24 by $2.19. TG Therapeutics had a net margin of 84.13% and a return on equity of 133.24%. The business had revenue of $161.71 million during the quarter, compared to the consensus estimate of $152.12 million. During the same period in the previous year, the company posted $0.02 earnings per share. The firm's revenue was up 92.7% on a year-over-year basis. Sell-side analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>TG Therapeutics（NASDAQ:TGTX - 获取免费报告）最近在 11 月 3 日星期一公布了其财报。该生物制药公司报告季度每股收益为 2.43 美元，超出分析师一致预期的 0.24 美元，差额为 2.19 美元。TG Therapeutics 的净利润率为 84.13%，股本回报率为 133.24%。该公司在本季度的收入为 1.6171 亿美元，而一致预期为 1.5212 亿美元。在去年同期，该公司每股收益为 0.02 美元。该公司的收入同比增长 92.7%。卖方分析师预测 TG Therapeutics, Inc. 本财年将发布 0.08 美元的每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other TG Therapeutics news, Director Yann Echelard sold 5,000 shares of the business's stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $32.57, for a total transaction of $162,850.00. Following the sale, the director owned 223,816 shares of the company's stock, valued at approximately $7,289,687.12. The trade was a 2.19% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Corporate insiders own 10.64% of the company's stock.</p>
<div class="lb-trans"><p>在其他 TG Therapeutics 的新闻中，董事 Yann Echelard 于 11 月 24 日星期一出售了 5,000 股该公司的股票，交易价格为 32.57 美元，总交易额为 162,850.00 美元。出售后，该董事持有 223,816 股公司的股票，价值约 7,289,687.12 美元。此次交易使其持股减少了 2.19%。该交易已在向证券交易委员会提交的文件中披露，文件可在此链接查看。公司内部人士持有该公司 10.64% 的股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several brokerages have commented on TGTX. HC Wainwright assumed coverage on TG Therapeutics in a research report on Monday, October 6th. They issued a &#34;buy&#34; rating and a $60.00 price objective on the stock. Wall Street Zen raised shares of TG Therapeutics from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Sunday, December 14th. Weiss Ratings restated a &#34;hold (c+)&#34; rating on shares of TG Therapeutics in a research note on Monday. B. Riley raised shares of TG Therapeutics to a &#34;strong-buy&#34; rating in a research report on Tuesday, November 4th. Finally, JPMorgan Chase &amp; Co. lifted their price target on shares of TG Therapeutics from $46.00 to $49.00 and gave the company an &#34;overweight&#34; rating in a research note on Monday, November 3rd. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat, TG Therapeutics presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $50.25.</p>
<div class="lb-trans"><p>几家券商对 TGTX 发表了评论。HC Wainwright 于 10 月 6 日星期一在一份研究报告中开始覆盖 TG Therapeutics。他们对该股票给予了 “买入” 评级，目标价为 60.00 美元。华尔街 Zen 在 12 月 14 日星期日的研究报告中将 TG Therapeutics 的评级从 “持有” 上调至 “买入”。Weiss Ratings 在周一的研究报告中重申了对 TG Therapeutics 的 “持有（c+）” 评级。B. Riley 在 11 月 4 日星期二的研究报告中将 TG Therapeutics 的评级上调至 “强力买入”。最后，摩根大通在 11 月 3 日星期一的研究报告中将 TG Therapeutics 的目标价从 46.00 美元上调至 49.00 美元，并给予该公司 “增持” 评级。一位研究分析师对该股票给予了强力买入评级，两位给予了买入评级，两位给予了持有评级。根据 MarketBeat，TG Therapeutics 目前的共识评级为 “适度买入”，平均目标价为 50.25 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on TGTX</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 TGTX 的最新研究报告</strong></p>
</div><h2>TG Therapeutics Profile</h2>
<div class="lb-trans"><h2>TG Therapeutics 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company's research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.</p>
<div class="lb-trans"><p>TG Therapeutics, Inc. 是一家总部位于纽约市的临床阶段生物制药公司，专注于开发针对血液恶性肿瘤和自身免疫性疾病的靶向疗法。该公司的研究策略侧重于通过新型抗体和小分子药物调节 B 细胞生物学。自 2003 年成立以来，TG Therapeutics 已建立了一个多元化的产品组合，旨在满足肿瘤学和免疫学领域未满足的医疗需求。</p>
</div><p>In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.</p>
<div class="lb-trans"><p>在 2022 年 12 月，TG Therapeutics 实现了其第一个商业里程碑，当 ublituximab-xiiy（与 Biogen 合作市场化的 Briumvi®）获得美国批准。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than TG Therapeutics</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Forget AI, This Will Be the Next Big Tech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 TG Therapeutics</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “3 美元 AI 奇迹股票” 即将爆发</li>
<li>是否可以从资本利得税中扣除任何费用？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>忘记 AI，这将是下一个重大科技突破</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding TGTX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 TGTX 持有股份的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 TG Therapeutics, Inc.（NASDAQ:TGTX - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEdUWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TGTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in TG Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 TG Therapeutics 吗？</h2>
</div><p>Before you consider TG Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 TG Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 TG Therapeutics 并不在名单上。</p>
</div><p>While TG Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 TG Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Osaic Holdings Inc.出售了 39,445 股 TG 治疗公司的股票，股票代码为$TGTX